Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized Trials.

JCO Precis Oncol · 2025 · PMC12262128 · PMID 40638873

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

By contrast, the ICI+anti-VEGF+SOC group showed a trend toward improved OS over the SOC group, but the difference was not statistically significant (HR, 0.91 [95% CI, 0.75 to 1.10]; P = .315; Fig 2 C).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.